Reishi and NF-kB Inhibition: The Anti-Inflammatory Pathway

Reishi (Ganoderma lucidum)

2 entry points in the NF-kB pathway

Reishi ganoderic acids interrupt NF-kB signaling at two independent locations: the TLR4 receptor upstream, and the IkBa phosphorylation step downstream. Most pharmaceutical anti-inflammatories target only one.

Wang et al., Life (Basel), 2024; Dudhgaonkar et al., Int Immunopharmacol, 2009

Human tissue

Liu et al. (2015) confirmed NF-kB downregulation using actual Crohn's disease mucosal biopsies — not a rodent model

TNF-α, IL-1β, IL-6, COX-2

all four major pro-inflammatory mediators are downstream targets of the NF-kB block (Dudhgaonkar 2009)

2026 meta-analysis

Pozzobon et al. (Pharmaceuticals, 2026) is the most current systematic review — confirmed consistent NF-kB inhibition across preclinical models

Wang et al., Life (Basel), 2024; Dudhgaonkar et al., Int Immunopharmacol, 2009

View as image ↗

Most inflammatory diseases don't have one cause. They have one switch that's stuck in the on position.

NF-kB — formally, nuclear factor kappa B — is a protein that acts as the master inflammatory signaling switch inside cells. When NF-kB is activated, it moves into the cell's nucleus and turns on genes for dozens of inflammatory proteins: TNF-alpha (a cytokine that drives fever and tissue damage), IL-1beta and IL-6 (cytokines that escalate the inflammatory cascade), and COX-2 (the enzyme that produces prostaglandins — the molecules that cause pain and swelling and that are the target of ibuprofen and naproxen).

Chronic inflammatory conditions — rheumatoid arthritis, Crohn's disease, asthma, lupus, atherosclerosis — all involve NF-kB activation that has become dysregulated. The signal stays on when it should turn off. Many pharmaceutical anti-inflammatory drugs work by blocking specific outputs of NF-kB (ibuprofen blocks COX-2 enzyme, TNF blockers like adalimumab neutralize TNF-alpha). Reishi's ganoderic acids work further upstream: they prevent NF-kB from being activated in the first place.

And they do it at two independent points in the signaling chain.

For the broader anti-inflammatory landscape of reishi, see reishi and inflammation: how ganoderic acids fight chronic inflammation. For what this means for specific inflammatory conditions, see reishi for inflammatory conditions: research across diseases. For the Reishi pillar overview, see what is reishi mushroom: the science behind the mushroom of immortality.

What NF-kB Is and Why It's the Target

NF-kB is not one protein — it is a family of transcription factors (proteins that switch genes on and off) that sit at the center of the inflammatory response. In a resting cell, NF-kB is held inactive by a security protein called IkBa (inhibitor of kappa B alpha). IkBa physically blocks NF-kB from entering the cell nucleus, where it would otherwise turn on inflammatory genes.

When cells receive an inflammatory signal — from bacteria, damaged tissue, cytokines, or other threats — a signaling cascade is triggered that phosphorylates IkBa (tags it with a chemical flag that marks it for destruction). Once IkBa is degraded, NF-kB is freed to enter the nucleus and activate its target genes.

The genes NF-kB activates include: TNF-alpha, IL-1beta, IL-6, COX-2, iNOS (nitric oxide synthase), and adhesion molecules that help inflammatory cells migrate to the site of injury. In acute inflammation, this is useful — the immune system deploys to fight infection or begin repair. In chronic inflammatory conditions, the cycle continues without appropriate resolution. NF-kB stays active. Inflammatory mediators remain elevated. Tissue damage accumulates.

This is why NF-kB is called the master inflammatory switch: it sits upstream of so many inflammatory endpoints that blocking it affects the entire cascade rather than just one output. It is also why NF-kB has been a pharmaceutical target for decades — though direct NF-kB inhibitors have proven difficult to develop without unacceptable immune suppression.

The Two Entry Points: How Ganoderic Acids Block NF-kB

The foundational study establishing reishi triterpenes as NF-kB inhibitors was published by Dudhgaonkar and colleagues in International Immunopharmacology in 2009.^[1]

Dudhgaonkar's team isolated triterpenes from Ganoderma lucidum and tested them in macrophages — the immune cells primarily responsible for initiating and sustaining inflammatory responses. The macrophages were stimulated with LPS (lipopolysaccharide), a bacterial membrane fragment that triggers strong inflammatory activation through NF-kB. The Ganoderma triterpenes suppressed NF-kB activation, reduced COX-2 expression, and lowered TNF-alpha production compared to untreated cells.

This study also established an important distinction: it was the triterpenes — specifically the ganoderic acids — that drove anti-inflammatory activity, not the polysaccharides. Polysaccharide fractions tested separately showed minimal anti-inflammatory effect in this cell model.

A 2024 five-year review of ganoderic acid research by Wang and colleagues in Life (Basel) mapped the pathway in more detail.^[3] Wang documented that ganoderic acids operate at two independent points in the NF-kB activation chain:

Point 1: TLR4 receptor (upstream). TLR4 — Toll-like receptor 4 — is a pattern recognition receptor on the surface of immune cells that detects bacterial signals and triggers the inflammatory cascade via an adapter protein called MyD88, which then activates TRAF6 (TNF receptor-associated factor 6), which ultimately phosphorylates IkBa to release NF-kB. Ganoderic acids bind to TLR4 and interrupt this chain at the entry point, before the cascade has even started.

Point 2: IkBa phosphorylation (downstream). Even if the TLR4 signal gets through, ganoderic acids also block the step where IkBa gets phosphorylated and degraded. By protecting IkBa from destruction, ganoderic acids keep NF-kB locked in its inactive complex even when the upstream signal is present.

This dual-entry blockade means reishi's effect is more comprehensive than drugs that target only one point in the cascade. Whether this translates to stronger anti-inflammatory effects in clinical settings — where multiple inflammatory pathways operate simultaneously — is not established from human trial data.

The Most Compelling Evidence: Human Crohn's Disease Tissue

The most significant clinical-proximity evidence for reishi's NF-kB inhibition comes from a 2015 study published in Inflammatory Bowel Diseases by Liu and colleagues.^[4]

The study used human Crohn's disease mucosal biopsies — tissue samples taken from the inflamed intestinal lining of patients with active Crohn's disease, not from rodents or cell lines. This is an important distinction. Rodent intestinal cells and human intestinal cells differ in receptor density, signaling pathway sensitivity, and inflammatory response characteristics. Results from human tissue have higher translational relevance than animal or cell culture results.

When Ganoderma triterpenoids were applied to these human intestinal biopsy samples, NF-kB signaling was significantly downregulated. Pro-inflammatory cytokine production was reduced in both the inflamed and non-inflamed tissue samples from the same patients. The effect occurred in tissues already showing active inflammatory disease — not just in tissue maintained in neutral conditions.

Crohn's disease is characterized by overactive NF-kB signaling in intestinal epithelial cells and immune cells of the gut wall. The Liu 2015 study directly addresses whether reishi triterpenoids can reduce that activation in human tissue from patients with the condition. No rodent experiment can answer that question equivalently.

This remains an in vitro study (the biopsies were treated in laboratory conditions, not given to patients). But the human tissue source makes it the strongest available evidence for biological plausibility in human inflammatory disease.

Human Ex Vivo Confirmation: Asthma Patient Immune Cells

A companion study from 2015 by the same lead author (Liu and colleagues, published in International Immunopharmacology) provided a second human data point from a different condition and a different compound.^[5]

This study focused on ganoderic acid C1 — a specific individual ganoderic acid rather than a mixed extract — and tested it in peripheral blood mononuclear cells (PBMCs), which are the immune cells that can be drawn from a blood sample and include T cells, B cells, monocytes, and NK cells. The PBMCs came from asthma patients, not healthy donors.

Ganoderic acid C1 suppressed TNF-alpha production in both mouse macrophages and the human asthma patient PBMCs. The effect was dose-dependent. The mechanism included both NF-kB and MAPK/AP-1 pathway suppression — AP-1 (activator protein 1) is a second transcription factor that cooperates with NF-kB in driving inflammatory gene expression.

This study established two things. First, the anti-inflammatory effects of ganoderic acids are not limited to experimental cell lines — they occur in immune cells from patients with an actual inflammatory condition. Second, specific individual ganoderic acids have their own activity profiles, not just the mixed-extract effects seen in broader studies.

The asthma context is relevant because asthma is characterized by Th2-driven airway inflammation, and TNF-alpha blockade is a research target for asthma treatment. Ganoderic acid C1's effect on human asthma patient immune cells is a more precise finding than general anti-inflammatory activity.

For a deeper look at the specific compound profile, see ganoderic acid A, B, and beyond: individual compound research. For the compound class overview, see ganoderic acids: the unique triterpenes in reishi.

Extending to Rheumatoid Arthritis: The JAK/STAT Overlap

NF-kB is the primary target of reishi's anti-inflammatory compounds, but it is not the only inflammatory signaling pathway they affect.

A 2023 systematic review by Meng and colleagues in Molecules examined Ganoderma lucidum polysaccharides (note: polysaccharides, not triterpenes) specifically for rheumatoid arthritis mechanisms.^[6]

The review found that GLP (Ganoderma lucidum polysaccharides) reduced synovial inflammation in collagen-induced arthritis mouse models through NF-kB pathway inhibition — consistent with the triterpene data — but also through a second inflammatory cascade called JAK/STAT. JAK/STAT (Janus kinase/signal transducer) is a parallel inflammatory signaling pathway that operates alongside NF-kB in autoimmune inflammation and is the specific target of newer RA drugs called JAK inhibitors (tofacitinib, baricitinib).

The Meng 2023 review also found that GLP suppressed Th17 cell differentiation — Th17 cells are T cells that produce IL-17, a cytokine particularly elevated in RA and involved in joint destruction. This adds a third mechanistic layer: not just NF-kB blockade, not just JAK/STAT inhibition, but also reduction of a specific inflammatory T cell type.

This evidence comes from polysaccharides rather than triterpenes — a different compound class with different mechanisms. It suggests reishi's anti-inflammatory effects involve multiple compound classes acting through multiple pathways simultaneously, rather than a single compound hitting a single target.

For a detailed explanation of the mechanistic difference between reishi's triterpenes and polysaccharides, see how reishi triterpenes differ from polysaccharides in mechanism.

What the 2026 Meta-Analysis Concluded

The most current synthesis of reishi's anti-inflammatory evidence comes from Pozzobon and colleagues, who published a systematic review and meta-analysis of Ganoderma lucidum triterpenes and anti-inflammation in Pharmaceuticals in 2026.^[2]

The Pozzobon 2026 analysis found that Ganoderma lucidum triterpenes consistently reduced inflammatory markers across preclinical models, with NF-kB inhibition confirmed as the primary mechanism. The meta-analytic effect size was meaningful. But the review also identified two important limitations.

First, effect sizes varied significantly by extraction method and specific triterpene composition. Not all reishi extracts contain the same ganoderic acid profile. A product standardized to ganoderic acid A content will behave differently from one standardized only to total triterpenoids or one that is not standardized at all.

Second, no human randomized controlled trials of reishi for inflammatory conditions have been published. The entire evidence base — including the Liu 2015 human tissue studies, which are the closest to clinical evidence available — consists of in vitro and ex vivo work. The question of whether the NF-kB inhibition documented in laboratory settings produces meaningful anti-inflammatory benefit in patients with inflammatory disease is not yet answered by controlled trial data.

The Pozzobon 2026 meta-analysis provides the strongest case that the preclinical signal is real and consistent. It cannot tell us whether clinical trials will confirm or fail to confirm that signal.